ANDREA GOODWIN: Open Payments
NPI 1922063429 · HUNTSVILLE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$406 in 12 payments from 8 companies in 2025. Trend: 2023 $81 · 2024 $180 · 2025 $406
Food & beverage: $212Education: $194
| Company | Payments | Amount |
|---|---|---|
| Exelixis Inc. | 2 | $194 |
| AstraZeneca Pharmaceuticals LP | 3 | $73 |
| Novartis Pharmaceuticals Corporation | 2 | $42 |
| GlaxoSmithKline, LLC. | 1 | $25 |
| Genentech USA, Inc. | 1 | $21 |
| Celgene Corporation | 1 | $19 |
| ARRAY BIOPHARMA INC | 1 | $17 |
| Genmab U.S., Inc. | 1 | $16 |
Products named: IMFINZI, PLUVICTO, OJJAARA, Venclexta, REBLOZYL, BRAFTOVI, KISQALI, Epkinly.
Industry payments across AL — which companies pay providers there.
